These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28716894)

  • 1. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination.
    Whitehead SS; Subbarao K
    Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003.
    Waickman AT; Friberg H; Gargulak M; Kong A; Polhemus M; Endy T; Thomas SJ; Jarman RG; Currier JR
    Front Immunol; 2019; 10():1778. PubMed ID: 31417556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
    Galula JU; Salem GM; Chang GJ; Chao DY
    Hum Vaccin Immunother; 2019; 15(10):2328-2336. PubMed ID: 31314657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human CD4
    Angelo MA; Grifoni A; O'Rourke PH; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
    J Virol; 2017 Mar; 91(5):. PubMed ID: 27974563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.
    de Silva AM; Harris E
    Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dengue vaccine candidates in development.
    Durbin AP; Whitehead SS
    Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine.
    Guy B
    Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.
    Durbin AP; Schmidt A; Elwood D; Wanionek KA; Lovchik J; Thumar B; Murphy BR; Whitehead SS
    J Infect Dis; 2011 Feb; 203(3):327-34. PubMed ID: 21208923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response to dengue virus and prospects for a vaccine.
    Murphy BR; Whitehead SS
    Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing a dengue vaccination programme-who, where and how?
    E Clapham H; A Wills B
    Trans R Soc Trop Med Hyg; 2018 Aug; 112(8):367-368. PubMed ID: 30016491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.
    Sun W; Eckels KH; Putnak JR; Lyons AG; Thomas SJ; Vaughn DW; Gibbons RV; Fernandez S; Gunther VJ; Mammen MP; Statler JD; Innis BL
    J Infect Dis; 2013 Mar; 207(5):700-8. PubMed ID: 23225894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue vaccines: Are they safe for travelers?
    Halstead SB; Aguiar M
    Travel Med Infect Dis; 2016; 14(4):378-83. PubMed ID: 27343438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines licensed and in clinical trials for the prevention of dengue.
    Torresi J; Ebert G; Pellegrini M
    Hum Vaccin Immunother; 2017 May; 13(5):1059-1072. PubMed ID: 28281864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines.
    Borges MB; Marchevsky RS; Carvalho Pereira R; da Silva Mendes Y; Almeida Mendes LG; Diniz-Mendes L; Cruz MA; Tahmaoui O; Baudart S; Freire M; Homma A; Schneider-Ohrum K; Vaughn DW; Vanloubbeeck Y; Lorin C; Malice MP; Caride E; Warter L
    PLoS Pathog; 2019 Apr; 15(4):e1007721. PubMed ID: 31009499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-dengue Vaccines: From Development to Clinical Trials.
    Pinheiro-Michelsen JR; Souza RDSO; Santana IVR; da Silva PS; Mendez EC; Luiz WB; Amorim JH
    Front Immunol; 2020; 11():1252. PubMed ID: 32655561
    [No Abstract]   [Full Text] [Related]  

  • 19. Call to action for dengue vaccine failure.
    Mahalingam S; Herring BL; Halstead SB
    Emerg Infect Dis; 2013 Aug; 19(8):1335-7. PubMed ID: 23876389
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.